Measurable residual disease (MRD; previously termed minimal residual disease) is an
independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is …

Prospective studies on the detection of minimal residual disease (MRD) in acute leukemia
patients have shown that large-scale MRD studies are feasible and that clinically relevant …

Purpose Half the patients with acute myeloid leukemia (AML) who achieve complete
remission (CR), ultimately relapse. Residual treatment-surviving leukemia is considered …

Real-time quantitative RT-PCR (RQ-PCR) is a sensitive tool to monitor minimal residual
disease (MRD) in leukemic patients through the amplification of a fusion gene (FG) …

Mounting evidence indicates that the presence of measurable (“minimal”) residual disease
(MRD), defined as posttherapy persistence of leukemic cells at levels below morphologic …

Purpose Allogeneic hematopoietic cell transplantation (HCT) benefits many patients with
acute myeloid leukemia (AML) in first remission. Hitherto, little attention has been given to …

Detection of minimal residual disease (MRD) has prognostic value in many hematologic
malignancies, including acute lymphoblastic leukemia, acute myeloid leukemia, chronic …

Capture and isolation of flowing cells and particulates from body fluids has enormous
implications in diagnosis, monitoring, and drug testing, yet monovalent adhesion molecules …

Minimal residual disease (MRD) assessment is standard in many hematologic malignancies
but is considered investigational in multiple myeloma (MM). We report a prospective …

Early response to induction chemotherapy is a predictor of outcome in acute myeloid
leukemia (AML). We determined the prevalence and significance of postinduction residual …